share_log

ノイルイミューン---急反発、タカラバイオとNIB103の開発に関する業務提携契約を締結

Noile Immun --- rapid rebound, signed a business alliance contract with Takara Bio on the development of NIB103.

Fisco Japan ·  Sep 25 19:30

$Noile-Immune Biotech (4893.JP)$Surged. Forge a business alliance agreement with Takara Bio to develop their in-house PRIME CAR-T cells NIB103 using cancer patients' own lymphocytes. Takara Bio will exclusively handle the production of clinical trial products and commercial products after market launch, bearing the costs related to the production of trial products. The company will exclusively handle the development tasks excluding manufacturing of NIB103 within Japan, as well as post-market sales, and bear the costs associated with them. The company will continue to exclusively own all rights related to the development, manufacturing, and sales of NIB103 overseas.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment